Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies. Integration of Advanced Modalities: Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs.

Digital Computational Pathology: Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making. Data Interpretation Reporting: Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights. Cross-functional Leadership: Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies.

Responsibilities

Scientific Leadership Execution: Perform and interpret multiplex spatial biomarker datasets to inform Translational hypotheses and clinical strategies. Establish QC standards for data acquisition and analysis. Cross-Functional Collaboration: Partner within Research and Clinical teams to integrate spatial biomarker findings into translational plans.

Collaborate with Systems Biology and Information Sciences teams to enable visualization tools External Partnership Management: Serve as primary scientific liaison to CROs for spatial biomarker workflows; review deliverables, troubleshoot issues, and drive continuous improvement. Capability Building: Document best practices and SOPs for spatial biomarker workflows; recommend platform upgrades and pilot evaluations. Required Skills, Experience Education: 10+ years in digital pathology/spatial biology within pharma, biotech, or CRO settings.

g. ); ability to translate complex data into actionable insights Execution Excellence: Bias for action; delivers high-quality analyses under tight timelines Collaboration Influence: Builds strong relationships across functions and with external partners; communicates clearly and persuasively. Innovation Continuous Improvement: Identifies opportunities to enhance workflows and adopt emerging technologies.

PhD/MD or equivalent in Cancer Biology, Translational Sciences, Pathology or related discipline. Preferred Skills: Hands-on experience with spatial pathology workloads. Familiarity with AI/ML-assisted pathology workflows and spatial statistics.

Proven ability to manage CRO relationships and deliver time-sensitive biomarker analyses. #LI-Hybrid #LI-LN1 The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in.

Director, Molecular Pathology, Translational Sciences, Translational Research.